Join

Compare · ONCR vs RGC

ONCR vs RGC

Side-by-side comparison of Oncorus Inc. (ONCR) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ONCR and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • RGC is the larger of the two at $2.83B, about 34.4x ONCR ($82.3M).
MetricONCRRGC
Company
Oncorus Inc.
Regencell Bioscience Holdings Limited
Price
-
-
Market cap
$82.3M
$2.83B
1M return
-
-34.86%
1Y return
-
-62.08%
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NASDAQ
NASDAQ
IPO
2020
2021
News (4w)
0
0
Recent ratings
0
0
ONCR

Oncorus Inc.

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.